Status:
UNKNOWN
GenoMed4ALL: Improving SCD Classification and Prognosis by AI
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Sickle Cell Disorders
Eligibility:
All Genders
1+ years
Brief Summary
GenoMed4All 'Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases' aims to advance on individual SCD patients' disease characterisation and to improve t...
Detailed Description
SCD is a chronic life-threatening multisystem disorder, autosomal recessively inherited, caused by the presence of abnormal hemoglobin S (HbS) resulting from the sickle mutation in the HBB gene. In sp...
Eligibility Criteria
Inclusion
- Patients older than 1 year, diagnosed with SCD, all genotypes.
Exclusion
- Patients treated with stem cell transplant or gene therapy.
- Patients younger than 1 year old.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06019208
Start Date
January 1 2021
End Date
December 31 2024
Last Update
April 12 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
APHP Henri Mondor
Créteil, France, 94000
2
APHP Necker
Paris, France, 75015
3
Azienda Ospedale Università Padova
Padua, Italy, 35121
4
UMC Utrecht
Utrecht, Netherlands, 3584